Skip to main content

Table 2 Significant factors in multivariate analysis

From: Local prostate cancer radiotherapy after prostate-specific antigen progression during primary hormonal therapy

  Hazard ratio 95% confidence interval P-value
Biochemical recurrence free survival    
T stage ≤2a 1.7 1.1-2.5 0.014
PSA <10ng/ml 1.9 1.2-2.8 0.003
no PSA progression vs. PSA pr. with HT 3.4 1.9-6.0 <0.001
no PSA progression vs. no HT 1.5 1.2-21 0.024
nadir ≤0.5 vs. >0.5 after initial HT 4.7 1.1-19 0.034
Disease specific survival    
Gleason score ≤6 4.0 1.8-9.1 0.001
no HT vs. PSA progression with HT 23 7.3-72 <0.001
no PSA progression vs. PSA pr. with HT 9.1 3.7-22 <0.001
Overall survival    
age <70years 2.6 1.5-4.4 <0.001
Gleason score ≤6 2.2 1.4-3.7 0.002
no HT vs. PSA progression with HT 5.2 3.6-9.4 <0.001
no PSA progression vs. PSA pr. with HT 7.2 3.9-14 <0.001
  1. Abbreviations: PSA = prostate-specific antigen; HT = hormonal therapy.